Inhibikase Therapeutics (IKT) Accumulated Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Accumulated Expenses data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 11.65% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 11.65% increase from a year earlier, with the FY2025 full-year figure at $3.3 million, up 226.5% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.3 million, down from $3.3 million in the prior quarter.
• Over the last five years, Accumulated Expenses for IKT reached as high as $3.6 million in Q2 2022 and fell as low as $200213.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $1.4 million across 5 years, with a median of $999303.0 in 2024.
• On a YoY basis, Accumulated Expenses climbed as much as 3461.93% in 2022 and fell as far as 78.08% in 2022.
• Year by year, Accumulated Expenses stood at $459997.0 in 2022, then surged by 391.3% to $2.3 million in 2023, then slumped by 55.78% to $999303.0 in 2024, then surged by 226.5% to $3.3 million in 2025, then sank by 30.01% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $2.3 million in Q1 2026, $3.3 million in Q4 2025, and $1.2 million in Q3 2025.